创新药泽立美乳膏获特应性皮炎临床指南重点推荐

Core Insights - The "Expert Consensus on the Treatment and Management of Atopic Dermatitis (2025 Edition)" has been published, providing standardized clinical application guidance for the innovative drug, Zeli Mei Ben Wei Mo De Ointment [1][2] - Atopic dermatitis (AD) has a prevalence rate of 10%-15% among children in China, making it the leading non-fatal skin disease burden [1] - The consensus emphasizes the importance of Zeli Mei Ben Wei Mo De Ointment as a treatment option for the two-thirds of patients with mild to moderate AD, based on research data from the Chinese population [1][2] Treatment Mechanism - Zeli Mei Ben Wei Mo De Ointment works by inhibiting type 2 inflammatory cytokines and repairing the skin barrier, specifically targeting IL-4/IL-13 induced tight junction damage [2] - Clinical trials indicate that the ointment can reduce and eliminate skin lesions while alleviating itching, with most adverse reactions being mild to moderate [2] Treatment Guidelines - The consensus provides clear guidelines for treating special areas and populations, recommending the use of moderately potent topical medications in sensitive areas to avoid the risk of skin atrophy from long-term corticosteroid use [2] - The dual mechanism of Zeli Mei Ben Wei Mo De Ointment offers unique advantages in addressing the inflammatory responses and barrier defects commonly seen in AD patients in China, particularly for children and those contraindicated for steroids [2] - The publication of the consensus aims to guide medical institutions in standardizing the selection of topical medications for AD, promoting the standardization of AD diagnosis and treatment in China [2]